Nanotechnology-based approaches for tuberculosis treatment

Mubarak, Mohamad Mosa; Ahmad, Zahoor

doi:10.1016/b978-0-12-819811-7.00009-6

Cited by 5 publications

(3 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The importance of organic nanomaterials such as liposomes and polymeric nanostructures, including dendrimers and micelles, and their role in the development of targeted drug delivery is well established (Mosa Mubarak and Ahmad, 2020). Several articles have addressed the treatment of TB using nanotechnology-based delivery systems (Banyal et al, 2013;Patricia Bento Da Silva et al, 2016a;Nasiruddin et al, 2017a), however, they only focus on treatments convenient for adult administration and have not addressed the potential use of nanotechnology in the treatment of paediatric TB.…”

Section: Introductionmentioning

confidence: 99%

Nanotechnological innovations in paediatric tuberculosis management: current trends and future prospects

Ajayi,

Poka,

Witika

2024

Front. Drug Deliv.

View full text Add to dashboard Cite

Paediatric Tuberculosis (TB) continues to be a major global cause of morbidity and mortality. Children are more prone to contracting TB, which can spread quickly to extrapulmonary infection sites. Although the pathophysiology of the disease, drug pharmacokinetics, and the therapeutic window in children differ from those of adults, the same drugs used to treat adult TB have long been utilised to treat paediatric TB infections. Since many current formulations such as tablets are unsuitable for children due to difficulty swallowing and risk of choking, adult medications are frequently used by breaking or crushing tablets to obtain a paediatric dose. This can result in inaccurate dosing due to pharmacokinetic differences in children which could subsequently lead to sub-therapeutic or toxic systemic concentrations. In addition, many of the medications used in the treatment of TB and most medicines in general, have a profoundly unpleasant taste to children causing them to reject and spit out medication which contributes to challenges with adherence, ultimately leading to treatment failure. The aforementioned demonstrates a huge need for the development of novel drug delivery formulations that are paediatric-friendly and address the limitations of current dosage forms. This review discusses the currently available oral paediatric formulations, recent developments of novel oral drug delivery systems studied to overcome the current problems associated with the treatment of tuberculosis in paediatrics and provides potential direction for future research through nanotechnology by using a SWOT analysis.

show abstract

Section: Introductionmentioning

confidence: 99%

Nanotechnological innovations in paediatric tuberculosis management: current trends and future prospects

Ajayi,

Poka,

Witika

2024

Front. Drug Deliv.

View full text Add to dashboard Cite

show abstract

“…Nanomedicine forms part of modern medicine strategies to address challenges of both infectious diseases such as tuberculosis [22] and non-infectious diseases such as cancer [23]. Tissue regeneration using nano-based devices coupled with drug delivery are currently being used in clinics to address diabetic wounds [24].…”

Section: Introductionmentioning

confidence: 99%

“…Nanomedicine forms part of modern medicine strategies to address challenges of both infectious diseases such as tuberculosis [22] and non-infectious diseases such as cancer [23]. Tissue regeneration royalsocietypublishing.org/journal/rsos R. Soc.…”

Section: Introductionmentioning

confidence: 99%

Nanomedicine-based strategies to improve treatment of cutaneous leishmaniasis

et al. 2022

View full text Add to dashboard Cite

Nanomedicine strategies were first adapted and successfully translated to clinical application for diseases, such as cancer and diabetes. These strategies would no doubt benefit unmet diseases needs as in the case of leishmaniasis. The latter causes skin sores in the cutaneous form and affects internal organs in the visceral form. Treatment of cutaneous leishmaniasis (CL) aims at accelerating wound healing, reducing scarring and cosmetic morbidity, preventing parasite transmission and relapse. Unfortunately, available treatments show only suboptimal effectiveness and none of them were designed specifically for this disease condition. Tissue regeneration using nano-based devices coupled with drug delivery are currently being used in clinic to address diabetic wounds. Thus, in this review, we analyse the current treatment options and attempt to critically analyse the use of nanomedicine-based strategies to address CL wounds in view of achieving scarless wound healing, targeting secondary bacterial infection and lowering drug toxicity.

show abstract